Terbufibrol

Overview

Terbufibrol is an orally active lipid-lowering agent. Terbufibrol inhibits hepatic Cholesterol 7 alpha-hydroxylase . Terbufibrol blocks a step between Acetate and HMG-CoA in the hepatic cholesterol synthesis process. Terbufibrol reduces serum total cholesterol , HDL , LDL , lipoprotein levels, and the cholesterol/phospholipid ratio, with dose- and sex-dependent changes in lipoprotein components. Terbufibrol exerts sustained cholesterol-lowering activity in baboons and rats. Terbufibrol can be used in research related to hypercholesterolemia.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Hypercholesterolemia | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Apolipoprotein | Products > Signaling Pathways > LDLR | Products > Signaling Pathways > Cytochrome P450

Product Information

• Catalog No.: HY-101812
• CAS No.: 56488-59-6
• Molecular Formula: C20H24O5
• Molecular Weight: 344.40
• Purity: 98.39%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (14.52 mM); Clear solution
• Availability: In-stock

Source

Original product source